| Aug 8 |
Altimmune GAAP EPS of -$0.35 misses by $0.01
|
| Aug 8 |
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
|
| Aug 7 |
Altimmune Q2 2024 Earnings Preview
|
| Aug 7 |
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
|
| Aug 1 |
With 56% ownership, Altimmune, Inc. (NASDAQ:ALT) boasts of strong institutional backing
|
| Aug 1 |
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
|
| Jul 25 |
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
|
| Jul 2 |
Altimmune to Participate at Leerink Partners Therapeutics Forum
|
| Jun 26 |
Altimmune CFO Richard Eisenstadt passes away
|
| Jun 26 |
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
|
